The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Here is all you want to know. Take a look at CEO open market stock purchase in 2008-2009
95000 shares between $10 - $13
Mr. Robert J. Coury , 49
Chairman and Chief Exec. Officer
25-Feb-09 10,000 MYL Purchase at $12.97 per share.
(Cost of $129,700)
24-Feb-09 15,000 MYL Purchase at $12.90 per share.
(Cost of $193,500)
23-Feb-09 25,000 MYL Purchase at $12.86 per share.
(Cost of $321,500)
27-Jul-08 30,591 MYL Option Exercise at $0 per share.
27-Jul-08 12,107 MYL Disposition (Non Open Market) at $13.26 per share.
(Value of $160,538)
31-Mar-08 8,512 MYL Disposition (Non Open Market) at $11.60 per share.
(Value of $98,739)
18-Mar-08 25,575 MYL Option Exercise at $0 per share.
18-Mar-08 10,131 MYL Disposition (Non Open Market) at $11.18 per share.
(Value of $113,264)
7-Mar-08 20,000 MYL Purchase at $10.14 per share.
(Cost of $202,800)
6-Mar-08 10,000 MYL Purchase at $10.74 per share.
(Cost of $107,400)
5-Mar-08 15,000 MYL Purchase at $10.91 per share.
(Cost of $163,650)